In Gene Editing, there is no one size fits all solution.

The idea behind EmendoBio began when a group of passionate graduates from the Weizmann Institute gathered around a whiteboard and asked a critical question – “How do we make CRISPR better?”

As the answer unfolded, a company was created around the idea to “work to make CRISPR fit each disease specifically instead of trying to make every disease fit into the standard CRISPR model”. It was clear to us that CRISPR-based genome editing was a revolutionary technology capable of dramatically evolving the way we treat diseases. But it was just as clear that the conventional model of CRISPR was limited by the imprecision of its editing function. We believed that we could unlock more potential through engineering, optimization, and extreme precision.

Bringing together more than 90 bold scientists across the fields of computational biology, protein engineering, and RNA guide design, we have relentlessly focused on overcoming the existing limitations of CRISPR-based genome editing to specifically and effectively target any gene, while eliminating off-target effects. Our technology is so specific that we can cut one allele at a time, opening new potential routes to treat difficult genetic indications like autosomal dominant diseases.